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Interaction between the genome and the environment has been widely discussed in the literature, but has the
importance ascribed to understanding these interactions been overstated? In this opinion piece, we critically
discuss gene-environment interactions and attempt to answer three key questions. First, is it likely that gene-
environment interactions actually exist? Second, what is the realistic value of trying to unravel these interac-
tions, both in terms of understanding disease pathogenesis and as a means of ameliorating disease? Finally,
andmost importantly, do the technologies andmethodologies exist to facilitate an unbiased search for gene-
environment interactions? Addressing these questions highlights key areas of feasibility thatmust be consid-
ered in this area of research.Introduction
Gene-environment interaction is a broad term encompassing
the synergistic effect of genes and the environment on a disease
or trait. In this instance, the term environment can be broadly
interpreted to include lifestyle factors in addition to the more
traditional physical, chemical, and biological exposures that indi-
viduals are subjected to in their occupational and domestic
surroundings. Inmanyways, the term gene-environment interac-
tion represents a new dimension of the long-standing ‘‘nature
versus nurture’’ debate. In part this reflects a growing realization
that the notion of nature or nurture is a false dichotomy and that
understanding how these two powerful forces interact is key to
unraveling disease pathogenesis (Levin, 2009; Rutter, 2002;
Wermter et al., 2010). In our opinion, a complete understanding
of the role of environment in disease cannot be achieved in isola-
tion, but rather must be viewed in the context of the genome and
its variety.
Finding reliable environmental modifiers and risk factors for
disease has long been a goal of the research community, and
more recently this aim has morphed to include understanding
how the environment and the genome interact. This latter aim
of understanding ‘‘G3E’’ has received much lip service and
funding dollars over the last decade. In this opinion piece we
pose and attempt to address several critical questions around
this topic. First, we ask, are such gene-environment interactions
likely to exist? Second, is there a pressing need to search for
gene-environment interactions? Third, and last, we question
whether such a search is feasible and if so, how it could be
done and what it is likely and unlikely to yield.
Question 1: Are Gene-Environment Interactions Likely
to Exist?
Environmental Influence in Disease: Guilt by Plausibility
In the first section of this opinion piece we aim to address the
question of whether gene-environment interactions are likely to
exist. The title of this section is not meant to minimize the impor-
tance of the role environment plays in disease. Rather, it is
intended to highlight a problem we face in considering and dis-196 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.cussing environment and disease, namely that there appears
to be a general willingness to embrace environmental factors
as a cause of disease because they are attractive and easy to
understand. Thus, particularly in the lay press, environmental
links to disease are highly publicized and, even when only based
on preliminary work with appropriate caveats from authors,
reach the status of accepted facts within a short period of
time. Numerous examples of this phenomenon exist, including
perhaps most famously the notion that MMR vaccination causes
autism, an idea based on weak data that was ultimately with-
drawn from publication (Lancet, 2010). The point we are making
here is not that the concept of environment as a contributor to
disease is wrong merely because it is easy to understand, but
rather that because it is so plausible and accessible as a cause,
the burden of proof for such factors should be set correspond-
ingly high.
Evidence of Genetic and Environment Influence
in Human Life and Disease
With this message of caveat lector in mind, know that it has been
quite convincingly argued that nearly all human diseases and
physiological traits involve genetic and environmental influences
to some extent (Khoury et al., 2005; Willett, 2002). Examples
abound: the average height and lifespan of a population grows
in concert with a nation’s economic prosperity, reflecting
improved nutrition and access to healthcare (Cavelaars et al.,
2000; Steckel, 2004), but there also exists a high heritability for
this trait with several known genetic variants associated with
height (Gudbjartsson et al., 2008; Lettre et al., 2008; Visscher
et al., 2008; Weedon et al., 2008). Lifestyle choices, such as
diet and exercise, influence not only an individual’s risk of devel-
oping some of the commonest diseases in Western societies,
such as diabetes (Williamson et al., 2004), coronary artery dis-
ease (Akesson et al., 2007), and cancer (Kolonel et al., 2004),
but also modulate the expression of those phenotypes in terms
of age at onset and clinical course (Hedba¨ck et al., 1993; Psalto-
poulou et al., 2010). Even the sine qua non of environmentally
based disorders, infectious diseases, are now recognized to
be significantly influenced by host-microorganism interactions
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(Burgner et al., 2006; Murphy, 1993).
Gene-environment interactions are not just relevant to disease
susceptibility, but alsomodify expression of those phenotypes in
terms of age of symptom onset and subsequent clinical course.
Even in monogenic diseases, such as Huntington’s disease,
environmental exposures may explain why one mutation carrier
develops symptoms several decades before another member
of the same family carrying an identical mutation (Wexler et al.,
2004). Mutations of the valosin-containing protein (VCP) gene
are a good example of the extreme clinical variability that can
be observed within families. Variants within this gene are associ-
ated with an unusual clinical triad of inclusion body myopathy,
Paget’s disease of the bone, and frontotemporal dementia
(Watts et al., 2004), but with different members within the
same family manifesting isolated weakness due to myopathy,
or distinct phenotypes involving bone or the frontal lobes (van
der Zee et al., 2009). The biological basis of this clinical hetero-
geneity is unknown, but environmental factors may be relevant.
Thus, our current concept of purely genetic or environmental
diseases needs to be rethought in terms of gene-environment
interactions (Khoury et al., 2005).
Gene-Environment Interactions Are Complicated
and Bidirectional
Although there are many examples of environmental and genetic
factors influencing the same disease or trait, it is muchmore diffi-
cult to describe exactly how these two forces might interact.
We should only consider that a true gene-environment interac-
tion is occurring when the two contribute to a trait in a multiplica-
tive, rather than additive, manner. This definition in itself may in
the strictest sense be quite limiting, as one can certainly imagine
a scenario wherein particular genetic influences exert no risk (or
influence) alone for disease, but rather require an environmental
trigger (perhaps coupled with a precise sequential timing) before
any increase in disease risk is noted.
While there is merit to the prevailing paradigm of environ-
mental factors causing disease in genetically susceptible individ-
uals, the interplay between genetics and the environment is likely
to bemultifaceted and reciprocal. Not only do exposures to envi-
ronmental agents lead to disease in those who carry specific
genetic risk variants, but genetic characteristics may also influ-
ence an individual’s predilection for certain behaviors that lead
to the exposure in the first place. Smoking represents a case in
point, where epidemiological studies showing the association
between smoking and lung cancer were first published in 1950
(Doll and Hill, 1950). While the fundamental view that the number
of cigarettes smoked by an individual directly correlates with
their risk of lung cancer is irrefutable, it is increasingly recognized
that certain individuals may be predisposed to begin smoking, or
to find it particularly difficult to quit smoking (Gerra et al., 2005;
Kremer et al., 2005). The neuronal substrate underlying these
addiction traits is significantly driven by genetics. Neurological
diseases also show evidence of genetic and environmental influ-
ences: education level and cognitively intense professions are
associated with a delayed onset of Alzheimer’s disease (AD)
(Meijer et al., 2009; Wilson et al., 2002), and exercise may be
associated with a decreased incidence of Parkinson’s disease
(PD) (Thacker et al., 2008). Both diseases have a substantive,and increasingly recognized, genetic component (Lambert
et al., 2009; Seshadri et al., 2010; Simo´n-Sa´nchez et al., 2009;
Satake et al., 2009; Hamza et al., 2010).
Thus, we come to the expected conclusion: there already
exists substantive evidence implicating the environment and
genetics in disease, and it is highly probably that many complex
interactions exist between these two factors as the underlying
causes and modifiers of disease.
Question 2: Should We Be Looking
for Gene-Environment Interactions?
Effect of Gene-Environment Data on Healthcare
Our second question focuses on whether the research com-
munity should be expending significant resources into finding
gene-environment interactions. The most obvious answer to
this question rests on the value this knowledge would provide
in the overall context of human disease. Many of the key
advances in medicine over the last century have arisen from a
better understanding of gene-environment interactions. Peyton
Rous shared the 1966 Nobel Prize in Physiology or Medicine
for his discovery of tumor-inducing viruses, and, more recently,
Stanley Prusiner received the same prize in 1997 for his
discovery of prions as infectious agents, where susceptibility
to neurodegeneration after environmental exposure is strongly
influenced by PRNP genotype (Parchi et al., 1996). Based on
this, observers have argued that a better understanding of the
interplay between genetics and the environment would have
enormous impact on healthcare delivery by shifting emphasis
away from treatment of disease toward primary disease preven-
tion (Khoury et al., 2005). More specifically, a detailed knowledge
of disease risk factors would allow the identification of suscep-
tible individuals that could then be specifically targeted for inter-
ventions. Certainly, the ability to postpone the onset of disease,
perhaps indefinitely, through targeted intervention is particularly
appealing in the context of neurological diseases where effective
treatments are lacking (Corella and Ordovas, 2005).
Despite these examples, it is not clear whether a detailed
knowledge about the interactions between genetics and envi-
ronmental factors would directly lead to a revolution in health-
care delivery. The key variables to consider are overall cost
and effectiveness of population-based disease screening and
intervention, and the benefit to society based on the incidence
of the disease and associated disability. One notable success
in this area has been the dramatic drop in the rate of myocardial
infarction over the last decade arising from routine screening for
and treatment of high cholesterol levels (Yeh et al., 2010), though
it is noteworthy that this improvement occurred independent
of more recent advances in genetics of coronary artery disease.
In contrast, MRI screening of a population looking for cerebral
vascular aneurysms, for example, would not be feasible in terms
of cost or scanning resources compared to the potential out-
come in terms of cost per quality-adjusted life years. However,
identification of the genetic defects underlying this condition
(Krischek and Inoue, 2006) would allow selection of at-risk indi-
viduals that could then be targeted for routine screening and
intervention. In that instance the cost-benefit ratio shifts in favor
of instituting primary prevention strategies, especially as the
cost of complete genomic sequencing continues to fall to theNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 197
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clinical test.
Pharmacogenomics Underlying Gene-Environment
Interactions
Pharmacogenomics represents a specialized example of gene-
environment interaction, especially when one considers that
the same liver enzymes that metabolize pharmaceutical agents
are also involved in the breakdown and excretion of chemical
environmental agents (Corella and Ordovas, 2005). A full discus-
sion of pharmacogenomics is beyond the scope of this article,
but it is clear that an enhanced knowledge of the genetic factors
within metabolic pathways that influence uptake, transport,
binding, and clearance of drugs will be directly relevant to under-
standing an individual’s response to environmental toxins. Even
in that instance, much remains to be elucidated in terms of the
importance of both genetics and environmental factor metabo-
lism before it can be applied to prevent or ameliorate disease.
Thus, in answer to our second question, we do believe there is
value to understanding the role of genetics and environment in
disease; such an understanding is likely to inform at the basic
biological level and ultimately move us closer to etiologic-based
treatments and preventative therapies. However, care should be
taken not to overstate the potential benefits that would be
derived from such knowledge.
Question 3: How Do We Go About Finding
Gene-Environment Interactions?
Our last question is designed to highlight the methodologies
available to us to find gene-environment interactions. This is
probably the most difficult question faced by the field at present,
because it implies that, even if gene-environment interactions
exist and even if improved understanding would have an appre-
ciable effect on healthcare, there would still be little point in trying
to unravel these interactions unless there is a reliable, high-
throughput method for detecting them in the first place. Implicit
in our question is the dichotomy in our current ability to identify
and modify genetic and environmental factors. On the one
hand, it is increasingly straightforward to identify genetic factors
underlying disease (Singleton et al., 2010), but these genetic
factors are immutable (at least for now). On the other hand, accu-
rate quantification of environmental exposures is laborious, but
identified factors are more amenable to modification as a means
to prevent or treat disease.
Collecting Environmental Data Is Complicated
Unraveling gene-environment interactions is complicated by the
difficulty in accurately and rapidly collecting lifetime environ-
mental data. The term ‘‘exposome’’ has been coined to encom-
pass all of the environmental exposures of an individual (Wild,
2005). In our opinion, this term is misleading, as it implies the
existence of a technology that reliably quantifies an individual’s
lifetime exposure. Instead, the vast majority of epidemiological
studies use self-reporting questionnaires to collect the neces-
sary environmental information, a process that relies on the
patient’s memory of the event in question and is subject to the
vagaries of recall bias. A number of issues further impede
the accurate collection of historical environmental data. First,
the timing of the exposure may be critical to the development
of the disease,meaning that a causative environmental exposure198 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.may have happened decades before symptom onset. For exam-
ple, fetal alcohol syndrome results only during a narrow window
of exposure in utero, and obtaining information fromparentsmay
be more appropriate in that instance. Distant exposures may
also be relevant to neurological diseases: mouse experiments
now suggest that head trauma, a known risk factor for later onset
of PD and AD, can give rise to persistent (lifetime) changes in
gene expression within the brain (Crawford et al., 2007). Second,
data collection using questionnaires is resource-intensive both
for the study subject and for the researcher, but briefer question-
naires run the risk of overlooking relevant data.
It is unlikely that a technology that accurately and rapidly
quantifies an individual’s environmental history (i.e., their expo-
some) will be developed in the foreseeable future. Metabolomics
has been proposed as a surrogate for measuring environmental
exposures (Corella and Ordovas, 2005; Ilyin et al., 2004), but this
overlooks the difficulty in deconvoluting the signal to determine
what arises from inherited genetic factors and what is a conse-
quence of external environmental exposures.
Data Release of Environmental Data Might Help
One immediate way to partially overcome this bottleneck in col-
lecting environmental data would be to place greater emphasis
on making existing population-based environmental data sets
standardized and publicly available. While it is correct that the
principal investigators of large epidemiological studies should
be allowed a period of time to analyze and publish their results,
there should be a concerted effort to make environmental data
publicly available alongside any corresponding genome-wide
data. Such large, well-curated data sets would be invaluable to
researchers around the world who wish to test specific gene-
environment interaction hypotheses. The cost, resources, and
time necessary to complete these large-scale epidemiological
studies make them essentially impossible to repeat within a
reasonable timeframe. Genome-wide and clinical data is already
made public in the dbGAP repository, clearly demonstrating that
the bioinformatic infrastructure for sharing environmental data
exists.
Collecting Genomic Data Is Tractable and Can Help
the Epidemiologists
In contrast to collecting environmental data, our technological
ability to examine the genome is advancing at a phenomenal
rate. As the cost of sequencing genomes continues to fall toward
the $1000 price tag (Carr, 2010), it will become feasible to identify
all genetic variants and structural abnormalities in large cohorts
of patients. Even today, genome-wide association studies have
been highly successful in identifying risk factors for com-
mon diseases (www.genome.gov/gwastudies). Information on
the underlying biology of disease obtained from genomics will
play an important role in the design of future analytical epidemi-
ological studies. Rather than pursuing the current strategy of
collecting the maximum amount of information per patient,
improved knowledge of biological pathways will guide epidemi-
ologists in their selection of which environmental data to collect
(Traynor, 2009). Such targeted study design will decrease costs
by decreasing sample size and by shortening completion time.
It will also have the advantage of decreasing the statistical
penalty accrued from the multiple testing involved in analyzing
superfluous variables.
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Understanding the biological mechanisms underlying gene-
environment interactions is in its infancy. While it seems fairly
likely that environmental factors work by altering cellular gene
expression, the exact cellular processes by which this occurs
are not known. A hypothesis that is gaining ground is that envi-
ronmental factors achieve their effect by altering the epigenetic
profile of the cell (Bjornsson et al., 2004; Corella and Ordovas,
2005). The availability of whole-genome array technology that
quantifies methylation in a genome-wide manner (as well as
that of next-generation sequencing protocols for bisulfate con-
verted DNA) makes it feasible to test this hypothesis. Genetic
variation also regulates genome-wide methylation patterns
(Gibbs et al., 2010), and thus may explain why certain individuals
are more susceptible to certain environmental agents. Tissue to
tissue variation in epigenetic patterns, as well as changes occur-
ring as part of development or the aging process, may also be
important and may explain why certain agents act in a tissue-
specific manner. Again, improved understanding of the effect
of environmental factors on the epigenetic profile of a tissue
will ultimately serve as a guide for epidemiologists in their choice
of environmental agents to evaluate in their studies.
Conclusion and Future Possibilities
In answer to our own questions, we believe that gene-environ-
ment interactions are central to human disease, and identifica-
tion of these interactions holds great promise for the treatment
and primary prevention of disease in the future. That being
said, our ability to routinely screen for and understand the
biology of gene-environment interactions is currently limited by
our inability to accurately and reliably quantify an individ-
ual’s environmental and lifestyle history. For now, technologi-
cal advances mean that the most logical and parsimonious
approach is to concentrate on gathering genomic and epige-
nomic data about human disease, which may then provide clues
as to which type of environmental factors should be measured in
epidemiological studies. In the not-too-distant future, the falling
cost of sequencing will make it fiscally reasonable to analyze
the genomes of all neonates to look for predisposition to the
whole gamut of common human diseases, similar to the current
neonatal screening program. Such an endeavor would greatly
facilitate our search for gene-environment interactions. Many
challenges exist for the identification of gene-environment
influences in disease. A primary limitation of such work will be
sample size; such interactions require considerable cohorts,
for discovery and replication. As a result one might suspect
that reliable interactions may only be identified in common
diseases, and some diseases may simply be too rare to afford
robust analyses. Further, we have to believe that there may be
both genetic and environmental effects that are simply too small
to detect. This being said, making the environmental data from
existing cohort studies publicly available, especially those
wherein genome-wide data is also available for the subjects,
will greatly facilitate hypothesis testing for specific gene-environ-
ment interactions. True, the old dogma of nature versus nurture
is dead, but unfortunately it has been replaced by a puzzle even
harder to solve.ACKNOWLEDGMENTS
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